Boston

Few cities anywhere match Boston's depth and consistency as a Life Sciences and Biotechnology M&A market, anchored by the research density of Kendall Square, Harvard, and MIT and powered by a mature investor ecosystem spanning Bain Capital Life Sciences and Third Rock Ventures. The region continuously produces breakthrough platforms - from gene therapy to oncology to AI-driven drug discovery - that attract the full force of global pharmaceutical consolidation. Beyond life sciences, Boston's deal landscape is strengthened by a resilient base of mid-market Healthcare Services and Technology businesses with highly bankable recurring revenue profiles. Investors prize the region's unmatched academic talent pipeline and its ability to generate proprietary pipeline assets at a cost basis meaningfully below New York or San Francisco comparables.

---